^
    Back
    Association details:
    Biomarker:BRAF L597S
    Cancer:Melanoma
    Drug:REC-4881 (MEK1 inhibitor, MEK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Cancer Discov
    Title:

    BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors

    Excerpt:
    A patient with BRAF L597S mutant metastatic melanoma responded significantly to treatment with the MEK inhibitor, TAK-733. Collectively, these data demonstrate clinical significance to BRAF L597 mutations in melanoma.
    DOI:
    10.1158/2159-8290.CD-12-0097